INFORMED CONSENT FORM
For Canadian Sites

Sponsor / Study Title:	**Crestone, Inc. / "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRS3123 COMPARED WITH ORAL VANCOMYCIN IN ADULTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION"**
Protocol Number:	**19-0021**
Principal Investigator: (Study Doctor)	**«PiFullName»**
Telephone:	**«IcfPhoneNumber»**
Address:	**«PiLocations»**

KEY INFORMATION

The purpose of this research study is to test if an investigational study drug (not approved by Health Canada or the United States Food & Drug Administration) (CRS3123) is a safe and effective study treatment of an infection due to a bacteria called Clostridioides difficile. This infection is sometimes referred to as CDI which is short for Clostridioides difficile infection (CDI). ***Crestone, Inc.*** is the company sponsoring this research study with support from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIH/NIAID).

The study will test two different doses of CRS3123 compared to a standard antibiotic treatment for this infection called vancomycin. CRS3123 is a drug with a new way of attacking CDI infection. If enrolled, you will be asked to complete at least 8 outpatient study visits over 70 days.

The study has a screening period to determine if you meet the required criteria to enroll in the study. During the study treatment period, each subject will receive capsules of study drug (containing CRS3123, vancomycin, or placebo) four times a day (at approximately 6-hour intervals) for 10 days. The study treatment will last 10 days. Then there will be a follow-up period from day 11 through day 70.

Since CRS3123 has only been tested in healthy subjects, the side effects are relatively unknown in patients with CDI. The healthy volunteers who received either a single dose or multiple doses had the following most reported adverse events including:

- Headache
- Abdominal pain
- Upset stomach
- Diarrhea
- Taste disturbance
- Some changes in laboratory tests including decreased hemoglobin, liver function, decreased blood calcium, and blood tests that may indicate altered function of the pancreas.

Your participation in this research study is completely voluntary, meaning that you may or may not choose to participate. To decide whether or not you want to be part of this research, the risks and possible benefits of the study are described in this form so that you can make an informed decision. This consent form describes the purpose, procedures, possible benefits and risks of the study. This form explains how your medical information will be used and who may see it. You may have a copy of this form to review at your convenience or to ask advice from others before signing and dating it.

Please read this form carefully. Take your time to ask the study doctor or study staff as many questions about the study as you would like. The study doctor or study staff can explain words or information that you do not understand. Reading this form and talking to the study doctor or study staff may help you decide whether to take part in the study or not. If you decide to take part in this study, you must sign your name at the end of this form and date it.

BACKGROUND AND PURPOSE

You are being invited to participate in this research study because you have primary episode or first recurrence of Clostridioides difficile (C. difficile) infection referred to as CDI. This means it is your first episode or that you have been treated for this infection in the past no more than one time before this current infection you have now.

C. difficile is a type of bacteria, which lives in the intestines of many people and animals and is also present in the environment in places such as soil and water. Diarrhea, the most common symptom of a CDI, may be caused by the use of some antibiotic therapies causing a change to the normal balance of the microflora (a complex community of naturally occurring bacteria that live in your intestines). When the intestinal microflora is out of balance, the C. difficile bacteria begin to grow and produce toxins causing diarrhea and other symptoms such as abdominal pain or tenderness, loss of appetite, low-grade fever, nausea and vomiting. Sometimes CDI can become severe causing bloody diarrhea and even death. It is for this reason that new treatments are being discovered and tested.

The purpose of this research study is to:

- Test the safety and effectiveness of the 2 dosages of the study drug***, CRS3123,*** compared with vancomycin.
- Test the amount of CRS3123 in your blood; this tells researchers how much time it takes for the study drug to be absorbed.
- To see how well this study treatment is impacting your symptoms and the quality of your life by using a Health-related quality of life (HRQoL) questionnaire.

This is a research study to test a new investigational drug (CRS3123). An investigational drug is one that is not approved by Health Canada or the United States Food and Drug Administration (FDA). It is being compared to vancomycin; this study drug may be available by prescription for CDI.

A total of 30-36 subjects are planned per study treatment type, for a total of ***90-108*** total subjects for the study.

WHAT WILL HAPPEN DURING THE STUDY

Your participation in this study will last approximately ***70 days*** and will include approximately up to ***8*** study visits to the study center.

It is anticipated that the total amount of blood taken for study assessments will not exceed 129 mL (milliliters), or about half a cup.

Screening:

Before any study-related tests and procedures are performed, you will be asked to read and sign and date this consent document. The following screening tests and procedures will then be performed to determine if you qualify to take part in this study:

- An interview to collect information on your current and past medical history; current and recent medications you take; and information about your CDI.
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and includes evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- You will be asked to have an electrocardiogram (ECG) done, which is a recording of the electrical activity of your heart
- Blood and urine samples will be collected to test the function of your major organ systems. These tests will be compared to the same blood tests that are done at a later visit, after taking study drug.
- Urine pregnancy testing will be done for all women of childbearing potential. Women who are post-menopausal less than one year will have a urine pregnancy test.

- You will receive your Daily Diary that will capture details for each of your bowel movements, any missed doses of the study drug, other new medications, and the questions about your CDI symptoms. The study staff will train you on how to use that paper booklet every day.
- A stool sample will be collected at screening to determine if you have the infection and the type of CDI you have. The stool sample will also be sent for cultures and analysis at designated labs.

If you qualify to take part in this study and go on to receive the study treatment, then the following will happen:

Study Treatment:

During the study treatment period, each subject will receive capsules of study drug (containing CRS3123, vancomycin, or placebo) four times a day (at approximately 6-hour intervals), by mouth, for 10 days. Everyone will get an active study drug (either vancomycin or CRS3123). No one will receive placebo alone.

If you agree to participate in this study, you will be randomly assigned (like the flip of a coin) to receive one of the following study treatments:

- Arm A: CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.

or

- Arm B: CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.

or

- Arm C: Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.

This random assignment to a study treatment is called "randomization." The study treatment randomization will be in a 1:1:1 ratio, which means there is a 1 out of 3 chance of being randomized to any of the 3 arms.

This is a "double-blind study" which means that you and your study doctor will not know which study treatment you are receiving. In case of an emergency, however, the study doctor can get this information.

Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm. A placebo study treatment is designed to appear very similar to the active study drug treatment being tested. In this study, the placebo looks exactly like the real study drug, but it does not have any active ingredients in it. When we talk about "study drug" or "study treatment" we are talking about both the placebo and the active study drug.

You will have the following study visits and undergo the following procedures:

Day 1 (Before taking Study Drug)

- Vital signs including temperature, pulse rate, respiratory rate, and blood pressure.
- Review of your current medications: you will be asked to list any medications that you have taken since your last visit.
- You will be asked to give a stool sample. Part of the stool sample will be stored for future analyses.
- Blood samples will be collected for pharmacokinetic (PK) tests. PK tests are research tests done to see how long the study drug remains in your body.
- Randomization - all inclusion and exclusion criteria need to be met before randomization to a study treatment arm. All participants will be randomized by a computer system.

Day 1 (After taking Study Drug)

- Routine blood tests to check your overall health.
- You will be asked to give a stool sample. Part of the stool sample will be stored for future analysis.
- Blood samples will be collected for pharmacokinetic (PK) tests. PK tests are research tests done to see how long the study drug remains in your body. The samples will be taken approximately 1 hour and 3 hours after taking the study drug.
- You will receive your Daily Diary that will capture details for each of your bowel movements, date and time of study drug dosing, concomitant medications, and the questions about your CDI symptoms and how much of a burden they are to you. The study staff will train you on how to use that paper booklet every day.
- The study staff will review clinical observations during your study site visit.
- You will be given enough study drug at enrollment for the first five days of dosing. You will take your dose with water approximately every 6 hours as instructed by the study site staff.

Day 2, Day 5, Day 7, and Day 8

- Complete your Daily Diary as instructed by the study site staff.
- You will take your study drug approximately every 6 hours with water and you will record if you missed any of the study drug in your Daily Diary.

Day 3, Day 6, and Day 9

- The study site staff will contact you on the phone to capture an update on your symptoms, new or ongoing health problems.
- Complete your Daily Diary as instructed by the study site staff.
- Study drug will be taken approximately every 6 hours with water and any doses missed will be recorded in your Daily Diary.

Day 4- clinic visit

- Blood samples will be collected for pharmacokinetic (PK) tests. PK tests are research tests done to see how long the study drug remains in your body. The samples will be taken pre-dose.
- Height and weight will be measured.
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- Daily Diary completion and review with study site staff.
- Routine blood tests to check your overall health.
- You will be asked to give a stool sample anytime pre-dose or post-dose. Part of the stool sample will be stored for future analysis.
- You will be given enough study drug for the next five days of dosing. You will take your dose with water approximately every 6 hours as instructed by the study site staff.

Day 10 - clinic visit

- Blood samples will be collected for pharmacokinetic (PK) tests. PK tests are research tests done to see how long the study drug remains in your body. The samples will be taken pre-dose, about 2-hours post-dose, and about 4 hours post-dose.
- Height and weight will be measured.
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- You will be asked to have an electrocardiogram (ECG) done, which is a recording of the electrical activity of your heart.
- Daily Diary completion and review with study site staff.
- Routine blood tests to check your overall health (about 10.5 mL [about 2 teaspoons] of blood will be drawn for these tests).
- You will be asked to give a stool sample anytime pre-dose or post-dose. Part of the stool sample will be stored for future analysis.
- You will return your empty study drug wallet or unused study drug to the study site staff.

After Study Treatment:

Because this is a research study, the study drug will be given to you only during this study and not after the study is over.

Follow Up Visit-1, Day 12 - clinic visit

- Height and weight will be measured
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- Daily Diary completion and review with study site staff. This is the final day the diary will be completed unless there is suspected reoccurrence of CDI during the follow up period.
- Routine blood test to check your overall health.
- You will be asked to give a stool sample. Part of the stool sample will be stored for future analysis

Follow Up Visit-2, Day 17 - clinic visit

- Height and weight will be measured
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- Routine blood tests to check your overall health.
- You will be asked to give a stool sample. Part of the stool sample will be stored for future analysis.

Phone contact- Day 24 and Day 31

- The study site staff will contact you on the phone to capture an update on your symptoms, new or ongoing health problems.

Follow Up Visit-3, Day 40 - clinic visit

- Height and weight will be measured.
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- Routine blood tests to check your overall health.

- Urine pregnancy testing will be done for all women of childbearing potential. Women who are post-menopausal less than one year will have a urine pregnancy test.
- You will be asked to give a stool sample. Part of the stool sample will be stored for future analysis

Follow Up Visit-4, Day 70 - clinic visit

- Height and weight
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- Routine blood tests to check your overall health.
- You will be asked to give a stool sample. Part of the stool sample will be stored for future analysis

Unscheduled Visit, Suspected Recurrence

If signs and symptoms of CDI recurrences are suspected at any point in the study prior to Follow up Visit-4 on Day 70, you will be asked to return for an unscheduled clinic visit.

- Height and weight.
- You will be asked to have your temperature, blood pressure, heart rate, breathing rate, weight and height taken.
- A complete physical examination evaluation will be performed and include evaluation of the head, eyes, ears, nose, and throat, neck, lungs, heart, chest, abdomen, extremities, neurological status, and skin.
- An interview to capture an update on your symptoms, new or ongoing health problems.
- Daily Diary completion and review with study site staff.
- Routine blood tests to check your overall health.
- You will be asked to give a stool sample. Part of the stool sample will be re-tested for *C. difficile* and part will be stored for future analysis.

EXPECTATIONS

If you participate in this study, you will be expected to:

- Complete a Daily Diary that will capture details for each of your bowel movements, date and time of study drug dosing, concomitant medications, and the questions about your CDI symptoms.
- Take your study drug as directed by the study doctor or his/her designee. Return to the study site for all study procedures. Continue taking all other medications as told to you by your doctor.

- Call the study site if you are hospitalized, visit an emergency room or urgent care, your diarrhea returns for more than one day, or you do not feel well.
- Refrain from consuming non-dietary probiotics include capsules, powders, or liquids that are nutraceutical probiotics [primary ingredient is bacteria or yeast]. Yogurt, kombucha, kimchi, kefir, brine pickles, cheese, and other foods that are considered "dietary probiotics" are permitted.)
- Refrain from consumption of grapefruit and its juices as well as nutraceutical supplements containing curcumin (i.e., turmeric) until 24 hours after the last dose of study medication
- Females: if of childbearing potential and sexually active use 2 methods of birth control from the screening period until 60 days after taking last dose of study drug.
- Males: use highly effective method of birth control if female partner is of childbearing potential and refrain from sperm donation for 2 months after your last dose of the study drug.

RISKS, SIDE EFFECTS, AND/OR DISCOMFORTS

For *CRS3123:*

CRS3123 and placebo were tested in normal healthy volunteers who received either a single dose or multiple doses and the most common reported adverse events included:

- headache
- abdominal pain
- upset stomach
- diarrhea
- taste disturbance
- Some changes in laboratory tests including decreased hemoglobin, decreased blood calcium, liver function, and function of the pancreas

For Vancomycin

Vancomycin capsules have been approved by the US Food and Drug Administration for the planned use and at the planned dose in this study. In studies done in humans, the most common side effects, occurring in at least 5% of people treated included:

- Nausea
- Stomach pain
- Vomiting
- Diarrhea
- Flatulence
- Fever
- Swelling of the legs
- Tiredness
- Urinary tract infection
- Low blood levels of potassium

- Back pain
- Headache

There is a chance that the kidneys can be injured, particularly in people over 65 years. This may be as serious as kidney failure; it may also be milder kidney impairment or just an increase in the blood level of creatinine, a substance that is an indicator of how the kidneys are working.

There have also been cases of hearing loss. Dizziness, ringing in the ears, or loss of balance have also been reported.

It is also possible to develop infections caused by bacteria that are resistant to vancomycin.

As with any drug, allergic reaction is possible which can sometimes be severe or potentially life-threatening. This is a possibility but, to date, no reports of allergic reactions have occurred. Some symptoms of allergic reactions are rash, wheezing, difficulty breathing, dizziness, fainting, swelling around the mouth or throat or eyes, a fast pulse, and sweating. Please seek treatment immediately and tell the study doctor and study staff if you have any of these symptoms, or any other side effects, during the study.

RISKS OF STUDY PROCEDURES

- **Blood samples:** Possible side effects from blood drawing include faintness, inflammation of the vein, pain, bruising, or bleeding at the site of puncture. There is also a slight possibility of infection.
- **Electrocardiogram (ECG):** Skin irritation is rare but could occur during an ECG from the electrodes or gel that is used.
- **Stool Sample:** When you need to take a stool sample at home, there may be a possibility that you soil your skin with stool from the collection container if you do not handle your stool collection according to the instructions.

If you are taking antidiarrheals you will be asked to stop taking these medicines (washout period) from randomization until after Follow up Visit 4 (day 70). During this time, your symptoms may not improve or may get worse. If your symptoms get worse, tell the study doctor immediately.

UNFORESEEN RISKS

Since the study drug is investigational, there may be other risks that are unknown. Additionally, there may be unknown risks to a pregnancy or unborn child if you or your female partner become pregnant.

CRS3123 may interfere with how some medications are processed by your body. If you are taking medications, it is important to inform your doctor to discuss if these medications might be impacted by CRS3123. He or she might make adjustments to your medication.

BIRTH CONTROL RESTRICTIONS

Taking the study drug may involve risks to a pregnant woman, an embryo, fetus (unborn baby) or nursing infant. Therefore, if you are pregnant, planning to become pregnant, planning to father a child, or are breastfeeding a child, you cannot participate in this study.

Females:

- If you are able to become pregnant, you should use an effective method of birth control while you are participating in this study and for 2 months after your last dose of the study drug. Acceptable methods of birth control for use in this study are hormonal contraceptive method (pill, patch, vaginal ring, or injection), Intrauterine device or system. These must be used with a barrier method (condoms, diaphragm, or cervical cap) with spermicide. The study doctor or study staff will discuss this with you. If you become pregnant while you are participating in this study or within 2 months after you have stopped taking the study drug, tell your study doctor or study staff immediately. The study drug will be stopped and your participation in this study will be ended. The study doctor will ask to follow the pregnancy to its outcome (birth, miscarriage, or abortion) and for up to 6-8 weeks after delivery.

Males:

In order to reduce the risk of pregnancy, you should use an effective method of birth control while you are participating in this study and for ***2 months*** after your last dose of the study drug. Acceptable methods of birth control for use in this study are complete abstinence, male vasectomy, or double barrier method (condoms plus spermicidal foam, cream, or gel). The study doctor or study staff will discuss this with you.

If your female partner becomes pregnant while you are participating in this study or within 2 months after you have stopped taking the study drug, tell your study doctor or study staff immediately. The study doctor will ask for permission to follow up with your partner and, with her consent, will follow the pregnancy to its outcome and for up to 6-8 weeks after delivery. Your partner will be provided with a consent form for this pregnancy follow-up.

ALTERNATIVES TO PARTICIPATION

You do not have to be in this study to receive treatment for your CDI. Your options may include:

- There may be other clinical research studies available to you.
- Standard antibiotic treatment with Vancomycin, Fidaxomicin, or Metronidazole or treatment with Fecal Microbiota Transplant.

Please talk to the study doctor about your options before you decide whether or not you will take part in this study.

NEW FINDINGS

Any new important information that is discovered during the study and which may influence your willingness to continue participation in the study will be provided to you in a timely manner by the study doctor or study staff.

BENEFITS

You may benefit as a result of your participation in this study. There is, however, no guarantee that you will benefit from your participation in this study. Information learned from the study may help other people in the future.

COMPENSATION FOR PARTICIPATION

«Compensation»

You will be paid up to a total of $_____ if you complete this study. You will be paid for the visits you complete according to the following schedule:

- Up to $_____ per visit for Visits Day 1, Day 4, Day 10, Follow up Visit 1, Follow up Visit 2, Follow Up Visit 3, and Follow up Visit 4.
- Up to $_____ per visit for Visits Day 3, Day 6, and Day 9.

If you do not complete the study, for any reason, you will be paid for each study visit you do complete.

You will be paid _____ *[“after each visit,” “at the end of study participation,” etc.]*.

If you have any questions regarding your compensation for participation, please contact the study staff.

CONFIDENTIALITY

Your identity will be kept confidential at all times, except where disclosure is required by law. As part of this research, the study doctor will collect the results of your study-related tests and procedures and may also access your personal medical records for health information such as past medical history and test results. Information from this study will be submitted to the sponsor, and to Health Canada and possibly to governmental agencies in other countries (U.S. Food and Drug Administration) where the study drug may be considered for approval. Information sent from the study site will be coded with your individual subject number, but will not contain your name. The results of this research study may be presented at meetings or in publications but your identity will not be disclosed.

To make sure that the health information collected in this study is accurate, it will need to be checked from time to time against your medical records. Some persons may need to see these records in order to monitor the research and verify the accuracy of the study data, including:

- a limited number of representatives from the study sponsoring drug company (namely its monitors and auditors),
- the research ethics review board – Advarra IRB (an independent ethics committee that reviewed the ethical aspects of this study to help protect the rights and welfare of study participants),
- government regulatory authorities including Health Canada, the United States FDA, and other foreign regulatory agencies.

Your study records including confidential information about you collected during the study will be kept at a secure location.

While every effort will be made to protect the privacy of your information, absolute confidentiality cannot be guaranteed. This does not limit the duty of the researchers and others to protect your privacy.

By signing and dating this information and consent form, you consent to the collection, access, use and disclosure of your information as described above.

A description of this clinical trial will be available on *http://www.ClinicalTrials.gov*, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

COMPENSATION FOR INJURY

If you become ill or are injured while you are in the study, get the medical care that you need right away. You should inform the healthcare professional treating you that you are participating in this study. If you tell the study staff that you think you have been injured, then they will help you get the care you need.

The sponsor will cover necessary medical costs not covered by the public health plan or your private medical insurance (if any). In general, no long-term medical care or financial compensation for research-related injuries will be provided by the NIH or the U.S. Federal Government. By signing and dating this document, you will not lose any of your legal rights or release anyone involved in the research from responsibility for mistakes.

COSTS

There is no cost to you, your private medical insurance (if any), or the public health insurance plan, for study procedures. The study drug, study-related procedures, and study visits will be provided at no charge for the duration of the study.

FUTURE RESEARCH STUDIES

Identifiers will be removed from your identifiable private information or identifiable biospecimens collected during this study and **could then be used for future research studies or distributed to another investigator for future research studies**. You may change your mind about secondary research and withdraw consent for the storage and use of your coded samples or information at any time. You will need to contact the study doctor using the contact information listed on page 1 of this form. We will do our best to follow your wishes but cannot promise that we will always be able to destroy your samples or data. For example, if your samples were already used, we would not be able to destroy them.

Blood and urine specimens remaining after clinical safety assessments are performed will not be stored for future use.

Excess/leftover blood and fecal specimens remaining after pharmacokinetic tests may be stored for up to 5 years for future analyses.

No human genetic (DNA) tests will be done on these samples. The results of any future testing will be kept confidential in the same way as the results of other testing done for this study.

_____ **YES**, you may store my excess/leftover blood and fecal samples for up to 5 years and use them for future research.

_____ **NO**, you may not store my excess/leftover blood and fecal samples for up to 5 years and use them for future research.

COMMERCIAL PROFIT

Your biospecimens collected during this study may be used for commercial profit (even if identifiers are removed) and **you will not share in this profit**.

CONFLICTS OF INTEREST

The policy of the NIH is to evaluate investigators at least yearly for any conflicts of interest. You may review the system for assessing conflicts of interest by checking the web site link: http://ethics.od.nih.gov/forms/Protocol-Review-Guide.pdf. Copies of the standards may also be requested by research subjects. Crestone, Inc., the company that makes CRS3123 and NIH are providing funding for this study.

CLINICALLY RELEVANT RESULTS

Research results that are clinically relevant, including individual research results, **will not be disclosed to you.**

GENOME SEQUENCING

Researchers will only look at the genetic information of the microbes found in your stool sample. The research **will not include study of any of your genetic information** by sequencing, or "reading," every letter in your DNA (your genome).

WHOM TO CONTACT ABOUT THIS STUDY

During the study, if you experience any medical problems, suffer a research-related injury, or have questions, concerns or complaints about the study, please contact the study doctor at the telephone number listed on the first page of this consent document. If you seek emergency care, or hospitalization is required, alert the treating physician that you are participating in this research study.

An institutional review board (IRB) is an independent committee established to help protect the rights of research subjects. If you have any questions about your rights as a research subject, and/or concerns or complaints regarding this research study, contact**:**

- By mail:
  Study Subject Adviser
  Advarra IRB
  6940 Columbia Gateway Drive, Suite 110
  Columbia, MD 21046
- or call **toll free**: 877-992-4724
- or by **email**: adviser@advarra.com

Please reference the following number when contacting the Study Subject Adviser: Pro00046410

VOLUNTARY PARTICIPATION / WITHDRAWAL

Your decision to participate in this study is voluntary. You may choose to not participate, or you may withdraw from the study for any reason without penalty or loss of benefits to which you are otherwise entitled and without any effect on your future medical care. However, please note that the FDA requires that any information collected up to the point of your withdrawal cannot be removed from the study.

For participants who discontinue prematurely during the study treatment period, an end of study treatment visit will be conducted as soon as possible after discontinuation of study drug and the study doctor and study staff will subsequently perform all assessments as specified for follow up visits.

The study doctor or the sponsor can stop your participation at any time without your consent for the following reasons:

- If it appears to be medically harmful to you;
- If you fail to follow directions for participating in the study;
- If it is discovered that you do not meet the study requirements;

- If the study is canceled; or
- For administrative reasons.

If you leave the study for any reason, the study doctor may ask you to have some end-of-study tests for your safety.

PRIMARY HEALTH CARE PROVIDER NOTIFICATION OPTION

I consent to having my family doctor or primary health care provider notified by the study site of my participation in this study and/or any significant findings related to my health (please check yes or no).

☐ **YES** (If yes, please complete the information below)
☐ **NO**

Name and address of family doctor or primary health care provider:	Name: Address:
Telephone and Fax Number:	Tel: Fax:

CONSENT

I have read and understand the information on all pages in this informed consent document. I have had an opportunity to ask questions and all of my questions have been answered to my satisfaction. I voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by signing and dating this consent document. I will receive a copy of this signed and dated consent document.

_____
Subject's Printed Name

_____ _____
Subject's Signature Date

_____
Printed Name of the Person Conducting the Consent Discussion

_____ _____
Signature of the Person Conducting the Consent Discussion Date